In 2005, a study began to evaluate the mechanism of action of CJC-1295 in subjects with immunodeficiency virus (HIV) associated with visceral obesity. In this study, the subjects would be presented with CJC-1295 for 3 months and followed by a 6 week follow-up period. However, this study was terminated during the recruitment process, and no related results were posted.
According to a Norwegian study, in 2009 a compound was submitted for analysis to evaluate whether it contained prohibited substances or not. The researchers of the Norwegian Doping Control Laboratory and School of Pharmacy reported that this substance was CJC-1295. In their published article they concluded that "CJC-1295 is a releasing factor for growth hormone".
